Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00669110 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00669110 is a Phase 2 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 40 participants.
The verdict
NCT00669110, a Phase 2 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder. A secondary aim is to evaluate the efficacy of DVS SR in the treatment of child and adolescent outpatients with major depressive disorder in an exploratory manner.
Interventions
- DRUG Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00669110
The ClinicalTrials.gov registry entry for NCT00669110 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) is the first listed.
NCT00669110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00669110 about?
NCT00669110 is a clinical study titled "Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder". The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder. A secondary aim is to evaluate the efficacy of DVS SR in the treatment of child and adoles...
What is the current status of trial NCT00669110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-05. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00669110?
The interventions under investigation include: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) (DRUG).
Who is sponsoring clinical trial NCT00669110?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.